Table of Contents

company-logo

Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of cell and gene therapy products in Europe and internationally. The company operates in two segments, Platform and Product. Its LentiVector platform technology integrates genes into non-dividing cells, including neurons in the brain and retinal cells in the eye, as well as accommodates various therapeutic genes. The company's products under development stage include Axo-Lenti-PD, a gene-based treatment for parkinson's disease; OXB-302, which is in pre-clinical stage for the treatment of haematological tumours; OXB-401 that is in pre-clinical stage for the treatment of liver indication; OXB-40X for liver indication; and OXB-40Y for liver indication. The company has partnerships with Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Immatics, Arcellx, and Vaccines Manufacturing and Innovation Centre. The company also has a research collaboration agreement with Circularis Biotechnologies to identify novel tissue specific promoters for in vivo lentiviral gene therapy products; Virica Biotech for scaling of viral medicines; Isolere Bio provides a platform technology for tackling downstream inefficiencies in the manufacturing of biologics; and BiologIC Technologies provides novel biocomputer system for viral vector development. Oxford Biomedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.

Oxford Biomedica Dividend Announcement

• Oxford Biomedica does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Oxford Biomedica dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Oxford Biomedica Dividend History

Oxford Biomedica Dividend Yield

Oxford Biomedica current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Oxford Biomedica stock? Use our calculator to estimate your expected dividend yield:

Oxford Biomedica Financial Ratios

P/E ratio-3.14
PEG ratio-3.14
P/B ratio6.74
ROE-202.50%
Payout ratio0.00%
Current ratio2.35
Quick ratio2.07
Cash Ratio1.38

Oxford Biomedica Dividend FAQ

Does Oxford Biomedica stock pay dividends?
Oxford Biomedica does not currently pay dividends to its shareholders.
Has Oxford Biomedica ever paid a dividend?
No, Oxford Biomedica has no a history of paying dividends to its shareholders. Oxford Biomedica is not known for its dividend payments.
Why doesn't Oxford Biomedica pay dividends?
There are several potential reasons why Oxford Biomedica would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Oxford Biomedica ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Oxford Biomedica has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Oxford Biomedica a dividend aristocrat?
Oxford Biomedica is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Oxford Biomedica a dividend king?
Oxford Biomedica is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Oxford Biomedica a dividend stock?
No, Oxford Biomedica is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Oxford Biomedica stocks?
To buy Oxford Biomedica you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Oxford Biomedica stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.